Arrowhead Pharmaceuticals, a leader in RNAi therapeutics, reported a significant insider sale amid a year of exceptional stock gains.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback